Anticoagulant News and Research

RSS

FamilyCord introduces start-of-the-art collection kit for cord blood banking industry

FamilyCord, a subsidiary of California Cryobank, is leading the charge in the private cord blood banking industry for safer, more effective collection kits. FamilyCord's start-of-the-art collection kit is redefining the scientific standards for collection and transport employed by the cord blood banking industry.

2 Mar 2010

Canyon Pharmaceuticals announces the availability of Iprivask inhibitor for prevention of DVT

Canyon PharmaceuticalsTM (www.canyonpharma.com) today announced the availability of Iprivask (desirudin for injection), the first direct thrombin inhibitor (DTI) approved in the United States by the Food and Drug Administration for the prevention of deep vein thrombosis (DVT), which may lead to pulmonary embolism in patients undergoing elective hip replacement surgery.

2 Mar 2010

Dabigatran as effective as warfarin in preventing subsequent strokes among atrial fibrillation patients

The drug dabigatran was as effective as the currently recommended drug – warfarin – in preventing a subsequent stroke among people with atrial fibrillation and prior stroke or transient ischemic attack – and it did so with less bleeding according to late-breaking science presented at the American Stroke Association's International Stroke Conference 2010.

27 Feb 2010

Rapid, multiplexed genotyping method to identify SNPs that affect warfarin dose developed

Researchers from the Ohio State University have developed a rapid, multiplexed genotyping method to identify the single nucleotide polymorphisms (SNPs) that affect warfarin dose. The related report by Yang et al, "Rapid Genotyping of SNPs Influencing Warfarin Drug Response by SELDI-TOF Mass Spectrometry," appears in the March 2010 issue of the Journal of Molecular Diagnostics.

26 Feb 2010

sanofi-aventis reports 2009 fourth-quarter and full-year net earnings

Commenting on the Group's 2009 performance, sanofi-aventis Chief Executive Officer Christopher A. Viehbacher said, "2009 was the first year of implementation of our new strategy. Major steps have already been achieved in strengthening our growth platforms and reinforcing our R&D pipeline while delivering a double-digit EPS(1) growth".

10 Feb 2010

People living with IBD are at high risk of blood clots

People living with Inflammatory Bowel Disease (IBD) are known to be at high risk of blood clots when admitted to hospital during a flare-up of their disease but now new research by scientists at The University of Nottingham has shown that those who are not admitted to hospital during flare-ups are also at risk.

10 Feb 2010

Excelsior Medical receives Canadian marketing license for new, pre-filled catheter lock syringe

Excelsior Medical Corporation, one of the leading manufacturers of pre-filled catheter flush syringes, today announced that it has received a Medical Device License from Health Canada for its new, pre-filled catheter lock syringe to be sold in the Canadian marketplace.

10 Feb 2010

Journal highlights toxic nature of herbal medicines

A University of Adelaide forensic pathologist has sounded a worldwide warning of the potential lethal dangers of herbal medicines if taken in large quantities, injected, or combined with prescription drugs.

9 Feb 2010

Joint Commission urges hospitals to take steps to prevent pregnancy-related deaths

Pre-existing medical conditions such as high blood pressure are putting women at greater risk for death during or shortly after pregnancy, according to a Joint Commission Sentinel Event Alert issued today.

27 Jan 2010

Centron receives agency of record assignments for FRAGMIN and GLIADEL Wafer medicines

HealthSTAR's Centron, a medical communications company, is pleased to announce that they have been awarded agency of record assignments for FRAGMIN® and GLIADEL® Wafer from Eisai Inc.

9 Jan 2010

IPMT procedure can benefit patients with acute deep vein thrombosis

Patients with acute deep vein thrombosis (DVT) develop potentially dangerous blood clots and can suffer severe leg pain and swelling. Doctors with Virginia Interventional & Vascular Associates (VIVA) report success over the past two years in treating acute DVT patients with a procedure called isolated pharmacomechanical thrombolysis (IPMT), which destroys clots much faster than traditional therapies.

7 Jan 2010

ARYx Therapeutics receives guidance in writing from FDA on tecarfarin

ARYx Therapeutics, Inc., a biopharmaceutical company, today announced that is has received guidance in writing from the U.S. Food and Drug Administration (FDA) confirming that the existing development pathway remains acceptable to seek regulatory approval of ARYx’s novel anticoagulant agent, tecarfarin (ATI-5923).

5 Jan 2010

Gore introduces PROPATEN Vascular Grafts with Integrated Rings

W. L. Gore & Associates (Gore) today announced it will expand its line of GORE PROPATEN® Vascular Grafts to include configurations with a unique, all ePTFE radial support that is concealed within the ultra-smooth graft wall and resists kinking and compression. The GORE PROPATEN Vascular Graft with Integrated Rings was introduced at the 2009 AIMsymposiumTM / VEITHsymposiumTM in November in New York City.

21 Dec 2009

Decision Resources: Atrial fibrillation drug market to increase more than sevenfold

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to the launches of several new agents, the atrial fibrillation drug market will increase more than sevenfold from $790 million in 2008 to $6.1 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

15 Dec 2009

Latest findings on how blood clots form can open door to the development of new drugs

The latest findings on how blood clots form could open the door to the development of new and better-targeted drugs for patients at risk of strokes or heart attacks.

11 Dec 2009

New guidelines on the management of antithrombotic agents for endoscopic procedures published

According to a new guideline from the American Society for Gastrointestinal Endoscopy (ASGE) regarding the management of antithrombotic agents for endoscopy, aspirin and/or NSAIDs may be continued for all elective endoscopic procedures.

9 Dec 2009

Generic erosion of premium-priced branded agents to offset sales of new agents

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that generic erosion of premium-priced branded agents will offset sales of new agents and will cause the acute coronary syndrome market for drugs in the hospital setting to decrease from $800 million in 2008 to $729 million in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

8 Dec 2009

PolyMedix to present data on its heptagonist compounds

PolyMedix, Inc. (http://polymedix.com), an emerging biotechnology company developing acute care therapeutic drug products for infectious diseases and cardiovascular disorders, announced that data will be presented on its heptagonist compounds at the annual meeting of the American Society of Hematology in New Orleans, Louisiana.

8 Dec 2009

Dabigatran etexilate prevents recurrent VTE with less bleeding than warfarin

Boehringer Ingelheim today announced very positive results from their landmark RE-COVER™ study – the most advanced trial programme assessing a novel oral anticoagulant in development for acute venous thromboemolism (VTE) treatment – presented at the American Society of Hematology Annual Meeting1 and published in the New England Journal of Medicine online.

7 Dec 2009

New oral drug is safe and effective to combat clotting disorder

A new study provides welcome news for patients with a common clotting disorder known as venous thromboembolism (VTE).

7 Dec 2009

Anticoagulant News and Research

FamilyCord introduces start-of-the-art collection kit for cord blood banking industry

Canyon Pharmaceuticals announces the availability of Iprivask inhibitor for prevention of DVT

Dabigatran as effective as warfarin in preventing subsequent strokes among atrial fibrillation patients

Rapid, multiplexed genotyping method to identify SNPs that affect warfarin dose developed

sanofi-aventis reports 2009 fourth-quarter and full-year net earnings

People living with IBD are at high risk of blood clots

Excelsior Medical receives Canadian marketing license for new, pre-filled catheter lock syringe

Journal highlights toxic nature of herbal medicines

Joint Commission urges hospitals to take steps to prevent pregnancy-related deaths

Centron receives agency of record assignments for FRAGMIN and GLIADEL Wafer medicines

IPMT procedure can benefit patients with acute deep vein thrombosis

ARYx Therapeutics receives guidance in writing from FDA on tecarfarin

Gore introduces PROPATEN Vascular Grafts with Integrated Rings

Decision Resources: Atrial fibrillation drug market to increase more than sevenfold

Latest findings on how blood clots form can open door to the development of new drugs

New guidelines on the management of antithrombotic agents for endoscopic procedures published

Generic erosion of premium-priced branded agents to offset sales of new agents

PolyMedix to present data on its heptagonist compounds

Dabigatran etexilate prevents recurrent VTE with less bleeding than warfarin

New oral drug is safe and effective to combat clotting disorder

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News